2918814-97-6
Chemical Structure
AZD3470
- CAS No.: 2918814-97-6
- Formula:C23H19F2N5O2
- Molecular Weight:435.43
InChIKey: ZGRIZLDGBRZWGC-QHCPKHFHSA-N
SMILES: FC1=CC(NC(CN2[C@]3(C4=C(C2=O)C=C(F)C=C4)CCN(CC#CC)C3=O)=C5)=C5N=C1N
Biological Activity: AZD3470 is an orally active MTA-cooperative PRMT5 inhibitor, selective for MTAP-deficient tumors. AZD3470 induces cell cycle G2/M phase alterations, DNA damage, apoptosis, and symmetric dimethylarginine reduction. AZD3470 alters alternative splicing, increases skipped exon events in DNA repair and cell cycle pathways, and inhibits cancer cell proliferation and tumor growth. AZD3470 can be used for the research of non-small cell lung cancer and MTAP-deleted solid tumors[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AZD3470 | 99.74% | AZD3470 is an orally active MTA-cooperative PRMT5 inhibitor, selective for MTAP-deficient tumors. AZD3470 induces cell cycle G2/M phase alterations, DNA damage, apoptosis, and symmetric dimethylarginine reduction. AZD3470 alters alternative splicing, increases skipped exon events in DNA repair and cell cycle pathways, and inhibits cancer cell proliferation and tumor growth. AZD3470 can be used for the research of non-small cell lung cancer and MTAP-deleted solid tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
[1].
Jelena Urosevic, et al. Abstract 4489: CAAP1 loss uncovers vulnerability of MTAP-
deficient NSCLC to PRMT5 inhibition with AZD3470. Cancer Res (2026) 86 (7_Supplement): 4489. - [2]. Smith JM, et al. Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation. J Med Chem. Published online May 22, 2026. [Content Brief]
Keywords
